Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bromocriptine in rheumatic and autoimmune diseases.

R W McMurray1

  • 1Rheumatology Section, G.V. (Sonny) Montgomery VA Hospital, MS, USA. Robert.McMurray@med.va.gov

Seminars in Arthritis and Rheumatism
|August 15, 2001
PubMed
Summary

Bromocriptine shows promise as a safe and effective adjunctive therapy for autoimmune diseases like rheumatoid arthritis and lupus. Further research is needed to confirm its benefits in treating these challenging conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of chronic exposure to DDT and TCDD on disease activity in murine systemic lupus erythematosus.

Lupus·2009
Same author

Hepatitis C virus and systemic lupus erythematosus.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Osteoarthritis of the sternoclavicular joint.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2008
Same author

Estrogen and progesterone modulate monocyte cell cycle progression and apoptosis.

American journal of reproductive immunology (New York, N.Y. : 1989)·2003
Same author

Sex hormones in the pathogenesis of systemic lupus erythematosus.

Frontiers in bioscience : a journal and virtual library·2001
Same author

Prolactin in murine systemic lupus erythematosus.

Lupus·2001

Area of Science:

  • Immunology
  • Endocrinology
  • Rheumatology

Background:

  • Prolactin, an anterior pituitary hormone, is implicated in the pathogenesis of various rheumatic and autoimmune diseases.
  • Bromocriptine, a dopaminergic agonist, may exert therapeutic effects by suppressing prolactin secretion and acting on peripheral dopamine receptors.

Purpose of the Study:

  • To review experimental and clinical data supporting bromocriptine's use as a nonstandard or adjunctive therapy in rheumatic and autoimmune diseases.
  • To evaluate bromocriptine's efficacy and safety in managing conditions such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

Main Methods:

  • Literature search of the National Library of Medicine and review of author's work and cited references.
  • Analysis of data from clinical therapeutic trials, case reports, and blinded studies involving bromocriptine.

Related Experiment Videos

Main Results:

  • Clinical trials indicate bromocriptine (2.5-30 mg/day) is effective with minimal side effects in treating rheumatic and autoimmune diseases.
  • Bromocriptine demonstrated immunosuppressive effects in RA patients, improving clinical outcomes and disability indices.
  • Studies showed bromocriptine reduced SLE flares and was comparable to hydroxychloroquine in managing lupus activity.

Conclusions:

  • Clinical observations and trials suggest bromocriptine is a potentially safe and efficacious alternative therapy for recalcitrant RA, SLE, Reiter's syndrome, and psoriatic arthritis.
  • Further double-blind, placebo-controlled studies are necessary to validate these findings and explore bromocriptine's full therapeutic potential.